MUC1 downregulation inhibits non‑small cell lung cancer progression in human cell lines

Xu,Tao; Li,Daowei; Wang,Hongmei; Zheng,Taohua; Wang,Guangqiang; Xin,Ying

doi:10.3892/etm.2017.5062

MUC1 downregulation inhibits non‑small cell lung cancer progression in human cell lines

Authors:
- Tao Xu
- Daowei Li
- Hongmei Wang
- Taohua Zheng
- Guangqiang Wang
- Ying Xin
View Affiliations

Affiliations: Department of Respiratory Medicine, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, P.R. China, Department of Respiratory Medicine, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China, Department of Intensive Care Unit, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, P.R. China, Department of Respiratory Medicine, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China, Department of Endocrine and Metabolic Diseases, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, P.R. China
Published online on: August 29, 2017 https://doi.org/10.3892/etm.2017.5062
Pages: 4443-4447

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mucin 1 (MUC1) is a transmembrane glycoprotein that is aberrantly unregulated in numerous types of cancer, including non‑small cell lung cancer (NSCLC), and serves a key role as an oncogene in the tumorigenesis of various human adenocarcinomas. Studies have indicated that MUC1 is involved in cell proliferation, invasion and migration. However, the role of MUC1 in NSCLC progression remains poorly understood. The aim of the present study was to investigate the role of MUC1 in stable MUC1‑low‑expression NSCLC cell lines that were generated by transfection with MUC1‑siRNA. Cell Counting Kit‑8 assay was preformed to determine the proliferation ability of NSCLC cells, while cell apoptosis was detected using flow cytometry. In addition, the mRNA and protein expression levels of MUC1 were detected by reverse transcription‑quantitative polymerase chain reaction and western blot analysis, respectively. Western blot analysis was also used for detection of other associated proteins. The results demonstrated that, compared with the control group, the cell proliferation ability was significantly declined in the MUC1 inhibition group, and the cell apoptosis rate was markedly increased. Inhibition of MUC1 gene in NCI‑H1650 cells suppressed cell proliferation and induced cell apoptosis. In addition, the protein expression levels of vascular endothelial growth factor (VEGF) and VEGF‑C were notably decreased by MUC1 inhibition, indicating the anti‑angiogenic effect of MUC1 downregulation. Furthermore, inhibition of MUC1 gene with MUC1‑siRNA significantly suppressed the phosphorylation of protein kinase B and extracellular signal‑regulated kinase. In conclusion, the findings indicated that silencing of MUC1 gene may inhibit the development of NSCLC cells.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Graham MV, Purdy JA, Emami B, Harms W, Bosch W, Lockett MA and Perez CA: Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 45:323–329. 1999. View Article : Google Scholar : PubMed/NCBI
3	Zhou YY, Hu ZG, Zeng FJ and Han J: Clinical profile of cyclooxygenase-2 inhibitors in treating non-small cell lung cancer: A Meta-Analysis of nine randomized clinical trials. PLoS One. 11:e01519392016. View Article : Google Scholar : PubMed/NCBI
4	Fenchel K, Sellmann L and Dempke WC: Overall survival in non-small cell lung cancer-what is clinically meaningful? Transl Lung Cancer Res. 5:115–119. 2016.PubMed/NCBI
5	Quéré G, Descourt R, Robinet G, Autret S, Raguenes O, Fercot B, Alemany P, Uguen A, Férec C, Quintin-Roué I and Le Gac G: Mutational status of synchronous and metachronous tumor samples in patients with metastatic non-small-cell lung cancer. BMC Cancer. 16:2102016. View Article : Google Scholar : PubMed/NCBI
6	Pope CA III, Burnett RT, Thun MJ, Calle EE, Krewski D, Ito K and Thurston GD: Lung cancer, cardiopulmonary mortality, and long-term exposure to fine particulate air pollution. JAMA. 287:1132–1141. 2002. View Article : Google Scholar : PubMed/NCBI
7	Kufe D, Inghirami G, Abe M, Hayes D, Justi-Wheeler H and Schlom J: Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma. 3:223–232. 1984. View Article : Google Scholar : PubMed/NCBI
8	Kim YS, Gum J Jr and Brockhausen I: Mucin glycoproteins in neoplasia. Glycoconj J. 13:693–707. 1996. View Article : Google Scholar : PubMed/NCBI
9	Al Masri A and Gendler SJ: Muc1 affects c-Src signaling in PyV MT-induced mammary tumorigenesis. Oncogene. 24:5799–5808. 2005. View Article : Google Scholar : PubMed/NCBI
10	Li Y, Liu D, Chen D, Kharbanda S and Kufe D: Human DF3/MUC1 carcinoma-associated protein functions as an oncogene. Oncogene. 22:6107–6110. 2003. View Article : Google Scholar : PubMed/NCBI
11	Xu M and Wang X: Critical roles of mucin-1 in sensitivity of lung cancer cells to tumor necrosis factor-alpha and dexamethasone. Cell Biol Toxicol. 33:361–371. 2017. View Article : Google Scholar : PubMed/NCBI
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) methods. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
13	Cook KM and Figg WD: Angiogenesis inhibitors: Current strategies and future prospects. CA Cancer J Clin. 60:222–243. 2010. View Article : Google Scholar : PubMed/NCBI
14	Arsham AM, Plas DR, Thompson CB and Simon MC: Akt and hypoxia-inducible factor-1 independently enhance tumor growth and angiogenesis. Cancer Res. 64:3500–3507. 2004. View Article : Google Scholar : PubMed/NCBI
15	Zhang Y, Jiang X, Qin X, Ye D, Yi Z, Liu M, Bai O, Liu W, Xie X, Wang Z, et al: RKTG inhibits angiogenesis by suppressing MAPK-mediated autocrine VEGF signaling and is downregulated in clear-cell renal cell carcinoma. Oncogene. 29:5404–5415. 2010. View Article : Google Scholar : PubMed/NCBI
16	Khodarev N, Ahmad R, Rajabi H, Pitroda S, Kufe T, McClary C, Joshi MD, MacDermed D, Weichselbaum R and Kufe D: Cooperativity of the MUC1 oncoprotein and STAT1 pathway in poor prognosis human breast cancer. Oncogene. 29:920–929. 2010. View Article : Google Scholar : PubMed/NCBI
17	Retterspitz MF, Monig SP, Schreckenberg S, Schneider PM, Hölscher AH, Dienes HP and Baldus SE: Expression of {beta}-catenin, MUC1 and c-met in diffuse-type gastric carcinomas: Correlations with tumour progression and prognosis. Anticancer Res. 30:4635–4641. 2010.PubMed/NCBI
18	Kaira K, Murakami H, Serizawa M, Koh Y, Abe M, Ohde Y, Takahashi T, Kondo H, Nakajima T and Yamamoto N: MUC1 expression in thymic epithelial tumors: MUC1 may be useful marker as differential diagnosis between type B3 thymoma and thymic carcinoma. Virchows Arch. 458:615–620. 2011. View Article : Google Scholar : PubMed/NCBI
19	Ohgami A, Tsuda T, Osaki T, Mitsudomi T, Morimoto Y, Higashi T and Yasumoto K: MUC1 mucin mRNA expression in stage I lung adenocarcinoma and its association with early recurrence. Ann Thorac Surg. 67:810–814. 1999. View Article : Google Scholar : PubMed/NCBI
20	Ren J, Agata N, Chen D, Li Y, Yu WH, Huang L, Raina D, Chen W, Kharbanda S and Kufe D: Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell. 5:163–175. 2004. View Article : Google Scholar : PubMed/NCBI
21	Gao J, McConnell MJ, Yu B, Li J, Balko JM, Black EP, Johnson JO, Lloyd MC, Altiok S and Haura EB: MUC1 is a downstream target of STAT3 and regulates lung cancer cell survival and invasion. Int J Oncol. 35:337–345. 2009.PubMed/NCBI
22	Ferrara N: Molecular and biological properties of vascular endothelial growth factor. J Mol Med (Berl). 77:527–543. 1999. View Article : Google Scholar : PubMed/NCBI
23	Kajita T, Ohta Y, Kinura K, Tamura M, Tanaka Y, Tsunezuka Y, Oda M, Sasaki T and Watanabe G: The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer. Br J Cancer. 85:255–260. 2001. View Article : Google Scholar : PubMed/NCBI
24	Karkkainen MJ and Petrova TV: Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene. 19:5598–5605. 2000. View Article : Google Scholar : PubMed/NCBI
25	Roberts N, Kloos B, Cassella M, Podgrabinska S, Persaud K, Wu Y, Pytowski B and Skobe M: Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer. 66:2650–2657. 2006.
26	Kawano T, Ahmad R, Nogi H, Agata N, Anderson K and Kufe D: MUC1 oncoprotein promotes growth and survival of human multiple myeloma cells. Int J Oncol. 33:153–159. 2008.PubMed/NCBI